Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company

Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand

Fineline Cube Oct 20, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced...

Company Drug

BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC

Fineline Cube Oct 20, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...

Company Deals

Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases

Fineline Cube Oct 20, 2023

Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...

Company Deals

MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates

Fineline Cube Oct 20, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...

Company

HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy

Fineline Cube Oct 19, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...

Company

Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion

Fineline Cube Oct 19, 2023

Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of...

Company Deals

Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics

Fineline Cube Oct 19, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with...

Company Deals

Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China

Fineline Cube Oct 19, 2023

Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...

Company Drug

AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment

Fineline Cube Oct 19, 2023

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...

Legal / IP

CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge

Fineline Cube Oct 19, 2023

The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA:...

Company Drug

Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023

Fineline Cube Oct 19, 2023

China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...

Company Drug

Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support

Fineline Cube Oct 19, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...

Company R&D

WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain

Fineline Cube Oct 19, 2023

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...

Company Deals

AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development

Fineline Cube Oct 19, 2023

AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens...

Company Drug

Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA

Fineline Cube Oct 19, 2023

Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...

Company Deals

Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services

Fineline Cube Oct 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...

Company Drug

Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management

Fineline Cube Oct 19, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...

Policy / Regulatory

NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices

Fineline Cube Oct 19, 2023

The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...

Company

Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand

Fineline Cube Oct 19, 2023

Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...

Company Drug

Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial

Fineline Cube Oct 19, 2023

Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...

Posts pagination

1 … 509 510 511 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.